Schroder Investment Management Group Invests $949,000 in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Schroder Investment Management Group purchased a new position in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 34,741 shares of the company's stock, valued at approximately $949,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC boosted its holdings in shares of BridgeBio Pharma by 85.8% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 1,022 shares of the company's stock worth $28,000 after purchasing an additional 472 shares during the period. Avanza Fonder AB bought a new stake in shares of BridgeBio Pharma in the 4th quarter worth about $181,000. First Bank & Trust purchased a new position in shares of BridgeBio Pharma during the 4th quarter worth about $205,000. Moss Adams Wealth Advisors LLC bought a new position in BridgeBio Pharma during the 4th quarter valued at about $208,000. Finally, Legato Capital Management LLC purchased a new stake in BridgeBio Pharma in the 4th quarter worth about $210,000. 99.85% of the stock is owned by institutional investors.

Analysts Set New Price Targets

BBIO has been the subject of a number of research analyst reports. Citigroup raised their price target on BridgeBio Pharma from $45.00 to $49.00 and gave the stock a "buy" rating in a research note on Friday, February 21st. Scotiabank raised their price target on shares of BridgeBio Pharma from $49.00 to $52.00 and gave the stock a "sector outperform" rating in a research note on Friday, February 21st. JPMorgan Chase & Co. boosted their price objective on shares of BridgeBio Pharma from $44.00 to $50.00 and gave the company an "overweight" rating in a research report on Monday, March 24th. HC Wainwright reiterated a "buy" rating and issued a $49.00 price target on shares of BridgeBio Pharma in a report on Thursday, February 13th. Finally, Evercore ISI raised their price objective on BridgeBio Pharma from $45.00 to $50.00 and gave the stock an "outperform" rating in a report on Monday, December 23rd. One equities research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat, BridgeBio Pharma has a consensus rating of "Moderate Buy" and an average target price of $52.64.

Remove Ads

Insider Buying and Selling

In other news, Director Andrea Ellis sold 30,000 shares of the stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $34.05, for a total value of $1,021,500.00. Following the completion of the sale, the director now owns 12,000 shares of the company's stock, valued at $408,600. This represents a 71.43 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Brian C. Stephenson sold 4,148 shares of the business's stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $36.16, for a total transaction of $149,991.68. Following the completion of the sale, the chief financial officer now owns 102,464 shares in the company, valued at approximately $3,705,098.24. This trade represents a 3.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 9,684,739 shares of company stock worth $326,958,651 in the last 90 days. Insiders own 24.66% of the company's stock.

BridgeBio Pharma Stock Up 5.0 %

Shares of BridgeBio Pharma stock traded up $1.60 on Friday, reaching $33.91. 2,149,631 shares of the stock were exchanged, compared to its average volume of 2,267,922. The firm has a market capitalization of $6.45 billion, a price-to-earnings ratio of -11.90 and a beta of 1.08. The business has a 50 day moving average price of $33.59 and a two-hundred day moving average price of $29.79. BridgeBio Pharma, Inc. has a twelve month low of $21.62 and a twelve month high of $39.47.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The company reported ($1.31) earnings per share for the quarter, missing analysts' consensus estimates of ($1.09) by ($0.22). The business had revenue of $5.88 million for the quarter, compared to the consensus estimate of $4.04 million. Research analysts forecast that BridgeBio Pharma, Inc. will post -3.67 EPS for the current year.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.